Xin Lang Cai Jing·2025-09-04 01:49Company Overview - Junshi Biosciences has seen a stock price increase of 73.44% year-to-date, with a 7.80% rise in the last five trading days, an 18.95% increase over the last 20 days, and a 22.64% increase over the last 60 days [2] - The company specializes in the research and industrialization of monoclonal antibody drugs and other therapeutic protein drugs, as well as providing technical services and technology transfer related to monoclonal antibody drug development [2] Financial Performance - For the period from January to June 2025, Junshi Biosciences reported revenue of 1.168 billion yuan, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, showing a year-on-year increase of 36.01% [2] Shareholder Information - As of June 30, 2025, the number of shareholders for Junshi Biosciences was 31,200, an increase of 5.88% from the previous period, with an average of 24,543 circulating shares per shareholder, a decrease of 5.56% [2] - The top ten circulating shareholders include notable ETFs, with 华夏上证科创板50成份ETF holding 29.7167 million shares (a decrease of 536,700 shares), and 易方达上证科创板50ETF holding 22.2132 million shares (an increase of 630,000 shares) [3]